Home » Market News » DirectorsTalk Highlights » Artificial Intelligence will Revolutionise Drug Discovery
Frontier IP Group Plc

Artificial Intelligence will Revolutionise Drug Discovery

New technologies are making their way into the healthcare industry and healthcare providers are already experimenting with advances such as smart pill technology, 3D-printed medication, and mobile apps. But probably the biggest potential lies in artificial intelligence (AI). For a growing number of industries, AI has brought a new era of automation and the wave of AI-driven innovation is also felt in the healthcare sector. Although it’s still a relatively new technology, investments in AI healthcare tech are surging. According to the research firm MarketsandMarkets, the global AI in healthcare market is expected to reach a value of $36.1 billion by 2025, compared to just $2.1 billion in 2018.

Exscientia is at the forefront of Artificial Intelligence-driven drug discovery and design. As at 8th January 2019, Frontier IP Group Plc (LON:FIPP) have a 3.3% holding in Exscientia. Frontier IP Group, through its subsidiaries, engages in assisting universities, research institutions, and companies in the commercialization and exploitation of their intellectual property (IP) in the United Kingdom.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.